Demand for Novo Nordisk's Weight Loss Pill Is Strong Out of the Gate. Is the Stock Due for a Big Rally?

Core Insights - Novo Nordisk received regulatory approval for its weight loss pill, the first oral GLP-1 drug, presenting a significant growth opportunity for the company [1] - The stock of Novo Nordisk has increased by approximately 26% as of January 26, 2026, outperforming the S&P 500, which rose by only 1.5% [2] - Demand for the Wegovy pill has been strong, with 18,410 prescriptions in the U.S. during its first full week of launch [3] Financial Performance - Novo Nordisk's growth rate is expected to improve in 2026 due to strong demand for its weight loss pill, following a previous reduction in sales growth guidance from 13%-21% to 8%-14% due to competition [4] - The company's stock fell by 41% last year, but it is currently trading at a price-to-earnings (P/E) multiple of 17, which is significantly lower than rival Eli Lilly's P/E of over 50, indicating potential for a rally [5] Market Outlook - There is potential for further stock price increases for Novo Nordisk in 2026, suggesting that it may still be an opportune time for investment [6] - Despite the positive outlook, Novo Nordisk was not included in a list of the top 10 stocks recommended by an analyst team, indicating some caution among analysts [7]